The PE Ratio as of November 2024 (TTM) for Eiger BioPharmaceuticals, Inc. (EIGR) is -0.03

According to Eiger BioPharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -0.03. This represents a change of -90.03% compared to the average of -0.30 of the last 4 quarters.

Eiger BioPharmaceuticals, Inc. (EIGR) Historical PE Ratio (quarterly & annually)

How has EIGR PE Ratio performed in the past?

The mean historical PE Ratio of Eiger BioPharmaceuticals, Inc. over the last ten years is -112.12. The current -0.03 PE Ratio has changed -97.37% with respect to the historical average. Over the past ten years (40 quarters), EIGR's PE Ratio was at its highest in in the March 2021 quarter at 76.90. The PE Ratio was at its lowest in in the June 2014 quarter at -318.11.

Eiger BioPharmaceuticals, Inc. (EIGR) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Eiger BioPharmaceuticals, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Eiger BioPharmaceuticals, Inc. (EIGR) Average PE Ratio

How has EIGR PE Ratio performed in the past?

The current PE Ratio of Eiger BioPharmaceuticals, Inc. (EIGR) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Eiger BioPharmaceuticals, Inc. (EIGR) PE Ratio vs. Peers

How is EIGR’s PE Ratio compared to its peers?

Eiger BioPharmaceuticals, Inc.’s PE Ratio is less than Spero Therapeutics, Inc. (3.99), greater than Bolt Biotherapeutics, Inc. (-0.38), greater than Coherus BioSciences, Inc. (-2.62), greater than Gracell Biotechnologies Inc. (-12.30), greater than Neoleukin Therapeutics, Inc. (-0.98), greater than Cingulate Inc. (-1.18), greater than Lyra Therapeutics, Inc. (-0.17), greater than Finch Therapeutics Group, Inc. (-1.35), greater than Applied Therapeutics, Inc. (-8.27), less than X4 Pharmaceuticals, Inc. (6.04), greater than Acumen Pharmaceuticals, Inc. (-2.73), greater than Inozyme Pharma, Inc. (-3.09), greater than Terns Pharmaceuticals, Inc. (-5.51), greater than Day One Biopharmaceuticals, Inc. (-17.12), less than Connect Biopharma Holdings Limited (8.69), greater than Eton Pharmaceuticals, Inc. (-32.19), greater than Nuvation Bio Inc. (-1.10), greater than Eledon Pharmaceuticals, Inc. (-2.72), greater than Spruce Biosciences, Inc. (-0.51), greater than Werewolf Therapeutics, Inc. (-1.83), greater than Unicycive Therapeutics, Inc. (-0.62), greater than Fusion Pharmaceuticals Inc. (-17.31),

Build a custom stock screener for Eiger BioPharmaceuticals, Inc. (EIGR) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Eiger BioPharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Eiger BioPharmaceuticals, Inc. (EIGR) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Eiger BioPharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.